Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine‐maintained heroin users

March 2, 2016

Abstract In spite of the clinical utility of buprenorphine, parenteral abuse of this medication has been reported in several laboratory investigations and in the real world. Studies have demonstrated lower abuse liability of the buprenorphine/naloxone combination relative to buprenorphine alone. However, clinical research has not yet examined the utility of the combined formulation to deter […]

Read the full article →

A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: Findings from a retrospective multisite study.

March 2, 2016

Conclusions: Comparable rates of illicit drug use at 6 months may be expected irrespective of maintenance medication, while increased retention may be expected for patients maintained on methadone relative to those maintained on Suboxone or Subutex. (PsycINFO Database Record (c) 2014 APA, all rights reserved) (Source: Experimental and Clinical Psychopharmacology)

Read the full article →

The multi-site prescription opioid addiction treatment study: 18-month outcomes

March 2, 2016

Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of […]

Read the full article →

The multi-site Prescription Opioid Addiction Treatment Study: 18-month outcomes

March 2, 2016

Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of […]

Read the full article →

BUNAVAIL (Buprenorphine And Naloxone) Film [BioDelivery Sciences International, Inc.]

March 2, 2016

Updated Date: Aug 6, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

Buprenorphine and buprenorphine/naloxone intoxication in children – how strong is the risk? – Soyka M.

March 2, 2016

Opioid maintenance therapy with methadone or buprenorphine is an established and first-line treatment for opioid dependence. Risk of diversion and toxicity of opioid prescription drugs, including buprenorphine, causes significant concerns. This is particul… (Source: SafetyLit: All (Unduplicated)) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

A ‘Missing Not at Random’ (MNAR) and ‘Missing at Random’ (MAR) Growth Model Comparison with a Buprenorphine/Naloxone Clinical Trial

March 2, 2016

ConclusionsThis performance comparison of three missing data strategies (latent growth model, Diggle‐Kenward selection model, Wu‐Carrol selection model) on sample data indicates a need for increased use of sensitivity analyses in clinical trial research. Given the potential sensitivity of the trial arm effect to missing data assumptions, it is critical for researchers to consider whether the […]

Read the full article →

Factors Affecting Noncompliance With Buprenorphine Maintenance Treatment

March 2, 2016

Conclusions:Patients founds to be noncompliant were more likely to suffer from comorbid psychiatric illness. Patients who tested positive for benzodiazepines or cannabis were more likely to be noncompliant with treatment. Although the rate of noncompliance (inaccurate pill count) was high, patients were still found to be taking their prescribed buprenorphine as evidenced by positive UDS […]

Read the full article →

A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences From Around the World

March 2, 2016

The objective was to facilitate understanding of diversion and misuse so that all factors influencing their expression (patient and provider characteristics and public policy) can be appreciated within a framework that also recognizes the benefits of addiction treatment. With this comprehensive perspective, further careful work can help determine how to minimize these behaviors without eroding […]

Read the full article →

SUBOXONE (Buprenorphine Hydrochloride, Naloxone Hydrochloride) Film, Soluble [Lake Erie Medical DBA Quality Care Products LLC]

March 2, 2016

Updated Date: Sep 4, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

← Previous Entries

Next Entries →